FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
Trump tells FDA to fund itself fully through industry fees; Astra’s CEO dumps Teva offer
This
week, Phispers brings you lots of regulatory news from the US, where the Trump
administration h